Why Great Science Doesn't Sell Itself - Fixing Clinical Research's Commercial Blind Spot

Episode 58

0:00-37:05

Pavel Trofimov spent roughly 15 years in international B2B sales across complex technical markets before moving into clinical research — where he noticed something the industry treats as normal. Founders, scientists and operational leaders were doing the delivery and the business development themselves. In most other regulated industries, that commercial work sits with a dedicated team. That gap became Lab-2-Business (L2B). Pavel's mission, in his own words: to help excellent scientific and technological companies be as deliberate about winning business as they are about delivering it. In this episode he unpacks the imbalance at the heart of clinical research — delivery machines built to be precise and never make mistakes, with almost no one positioned to make the value clear and turn it into revenue. He's sharp on why founder-led growth hits a ceiling, why he refuses "twin mandates" (so he never becomes the networking "head that changes its body" at every conference), and why he rejects the word "fractional" altogether — he embeds as an extended team member, aligned on scope and outcomes, in it for the long run. The conversation's most provocative turn is on AI-native startups. Pavel argues they face a harder sell than anyone: they're not selling a product into the clinical trial ecosystem, they're selling behaviour change — convincing people to change how they work, measure and invoice.

Publisher

Adam Walker’s Pharma Prescribed Podcast

Link

pharmaprescribed.podbean.com/e/why-great-science-doesnt-sell-itself-fixing-clinical-researchs-commercial-blind-spot/

Published

October 6, 2026

Duration

37 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Adam Walker

AW

Adam Walker’s Pharma Prescribed Podcast

@adamwalkerspharmaprescribedp

#sciencedoesntsell #fixingclinicalresearchs #lifesciences #management

The Nile